reference/14806549

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14806549

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, Non-P.H.S.
issn	1465-542X 1465-5411
issueIdentifier	1
pageRange	19-
publicationName	Breast cancer research : BCR
startingPage	19
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c81c82b4ad9caa060230b3c9689699b7 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_cf5b9d5995507abc870f68cd20a978d7
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3f6ffae56358d2ee021723b7e2e26fd9 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_a8140cc1230f5d0c13459f2d2b17893e http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6357e7d96ac5bc0b1ad1b49f1117e000 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_55ebfc6d604425cac08fd5207ffd00d4 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_191d2a2619729daa72f0fecb3247f4c5 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6094ec282fc91d4c7a703a412e3505b6 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_00150d8f858f7c5ffb0914a268b91195 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5d79a8e1f4e45e7eac031cf9559107f1 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_fa1603687c2691678fd54ac6465fb136 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c99054ddc5fb9731b052b1bfd9cd51fe http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_94ce4c88a049dcc075a5287213b3e1b7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f6a437af18966eed9f247c0c04f20a52 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_44aed70c341a11cb0e02ea610f667045
bibliographicCitation	Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast Cancer Research. 2015 Feb 11;17(1):19. doi: 10.1186/s13058-015-0524-0.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_862cbefae7c8f384a43fabdb48458860 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_18787333c5724d00f3f41dc10f4ab4f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f4089abde598e87ff99f08410e25eb3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c503ed58b8defe942cf5823fe03c26a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b3346eea28e673ad2fb4ee5f51728c9b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_09cbc2f6a606d71326090559cf2dd091 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c77366789121c1dbc28858da5d2f55d
date	2015-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/25837326 https://doi.org/10.1186/s13058-015-0524-0 https://pubmed.ncbi.nlm.nih.gov/PMC4344788
isPartOf	https://portal.issn.org/resource/ISSN/1465-542X https://portal.issn.org/resource/ISSN/1465-5411 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21884
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
discusses	http://id.nlm.nih.gov/mesh/M0019167 http://id.nlm.nih.gov/mesh/M0028197 http://id.nlm.nih.gov/mesh/M0406100 http://id.nlm.nih.gov/mesh/M0589012 http://id.nlm.nih.gov/mesh/M0496339 http://id.nlm.nih.gov/mesh/M0232027 http://id.nlm.nih.gov/mesh/M0406104
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.11.22 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7dea3d19611618c75b9a5e73da3a984b http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b77e41c8d2fcc93d222a4b7c254e1d72 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7687b330ee9f6f96598432fe888e2a7c http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_de0fda59269934519ab758a157d7a2ab http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d438082aa318e9d26125c49dd33692c2 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_411dabb6f9bf2eafd7e325579645e525 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0ca83df0d1a33da99160cbd4b816c5db http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8120cee817441674cc4832d418b796c1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7be67cfe0bd2b71a5dc300c2e39cc966 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f9aca819e89a671bb5b25d9c153ec3a2 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ba986895c0877675ae0b94126b3bbb68 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3199bed6bde12d8a484bd51c47b9a775

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1457 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID984

Total number of triples: 68.